October 1, 2009
By:Brett Feret, PharmD
Fampridine-SR is a sustained-release oral medication that is pending FDA approval for the symptomatic treatment of multiple sclerosis (MS).
 |
October 1, 2009
By:Steven B. Russek, RPh
Specialty pharmacies are uniquely positioned to play a key role in the implementation of Risk Evaluation and Mitigation Strategies (REMS).
|
September 1, 2009
By:Olivia J. Phung, PharmD, Craig I. Coleman, PharmD
Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
|
August 1, 2009
By:Teresa K. Hoffmann, PharmD, CACP, CDE, CLS, Mary Ann Tucker, PharmD, Debra L. Parker, PharmD, CACP, CDE, CLS
This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.
|
July 1, 2009
By:Deborah A. Cios, PharmD, Julie E. Kim, PharmD, MBA, BCPS
Milnacipran was recently approved by FDA for the management of fibromyalgia syndrome. Clinical trials have demonstrated that this agent may be a reasonable alternative or adjunct therapy for patients with fibromyalgia syndrome who are unable to tolerate first-line tricyclic antidepressant therapy.
|
June 1, 2009
By:Kimberly Lenz, PharmD, Karen Coderre, PharmD, BCPP, Mark D. Watanabe, PharmD, PhD, BCPP
This review addresses the prevalence and management of major depressive disorder (MDD) in school-aged children and adolescents, including treatment guidelines and agents under investigation for this indication.
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.